Congress Materials – Fall Clinical Dermatology Conference (FCDC 2025)
2025 Fall Clinical Dermatology Conference | Oct 23-26 | Las Vegas, NV
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Durability of Response to the Targeted Oral Peptide Icotrokinra for High-Impact Site Psoriasis: 1-Year ICONIC-TOTAL Findings
This document will be available on October 23rd 2025
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide, in Adolescents With Moderate-to- Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3 Randomized, Double-blind, Placebo-Controlled Study (ICONIC-LEAD)
This document will be available on October 23rd 2025
Icotrokinra Demonstrated Superior Responses Compared With Placebo and Deucravacitinib in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3 ICONIC-ADVANCE 1&2 Studies
This document will be available on October 23rd 2025
Impact and Insights of Psoriasis on Quality-of-Life and Shared Decision-Making among US Adolescents and Adults
This document will be available on October 23rd 2025
Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study
This document will be available on October 23rd 2025
SPECTREM: Effect of Guselkumab on Psoriasis Severity Through Week 48 in Participants with Low BSA, Moderate Psoriasis
This document will be available on October 23rd 2025
SPECTREM: Effect of Guselkumab on Psoriasis Signs and Symptoms Through Week 48 in Participants with Low BSA, Moderate Psoriasis
This document will be available on October 23rd 2025
SPECTREM: Guselkumab Efficacy and Patient-Reported Outcomes Through Week 48 Across Multiple High-Impact Sites in Participants with Low Body Surface Area (BSA), Moderate Plaque Psoriasis
This document will be available on October 23rd 2025
SPECTREM: Guselkumab Impact on Nail Psoriasis and Psoriatic Arthritis Through Week 48 in Participants With Low BSA, Moderate Psoriasis With High-Impact Site Involvement
This document will be available on October 23rd 2025
SPECTREM: Primary Skin Clearance Through Week 48 With Guselkumab in Participants with Low Body Surface Area, Moderate Plaque Psoriasis
This document will be available on October 23rd 2025
Unmet Needs and Disease Burden Perspectives from Adults
This document will be available on October 23rd 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
